TY  - CONF

T1  - Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial (S36.004)

JO  - Neurology

UR  - https://doi.org/10.1212/wnl.90.15_supplement.s36.004

PY  - 2018/04/10

AU  - Burt RK

AU  - Balabanov R

AU  - Snowden JA

AU  - Sharrack B

AU  - Oliveira MC

AU  - Burman J

ED  - 

DO  - DOI: 10.1212/wnl.90.15_supplement.s36.004

PB  - Ovid Technologies (Wolters Kluwer Health)

VL  - 90

IS  - 15_supplement

Y2  - 2025/11/15

ER  -